ECSP089023A - Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico - Google Patents

Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico

Info

Publication number
ECSP089023A
ECSP089023A EC2008009023A ECSP089023A ECSP089023A EC SP089023 A ECSP089023 A EC SP089023A EC 2008009023 A EC2008009023 A EC 2008009023A EC SP089023 A ECSP089023 A EC SP089023A EC SP089023 A ECSP089023 A EC SP089023A
Authority
EC
Ecuador
Prior art keywords
fenetil
amino
methyl
benzoic
carboxibutil
Prior art date
Application number
EC2008009023A
Other languages
English (en)
Inventor
Bernd Kuehn
Daniel Wagner
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ECSP089023A publication Critical patent/ECSP089023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una formulación farmacológica acuosa que contiene ácido 4-[((4-carboxibutil)-{2-[(4-fenetilbencil)oxi]fenetil}-amino) metil]benzoico o una de sus sales. En especial, la presente invención se refiere a una formulación farmacológica acuosa que contiene ácido 4-[((4-carboxibutil)-{2-[(4-fenetilbencil)oxi]fenetil}amino)metil]benzoico o una de sus sales y amino-2-(hidroximetil)-2-propanodiol-1,3 (trometamol).
EC2008009023A 2006-07-06 2008-12-30 Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico ECSP089023A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006031175A DE102006031175A1 (de) 2006-07-06 2006-07-06 Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur

Publications (1)

Publication Number Publication Date
ECSP089023A true ECSP089023A (es) 2009-01-30

Family

ID=38330492

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008009023A ECSP089023A (es) 2006-07-06 2008-12-30 Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico

Country Status (33)

Country Link
US (1) US20100069493A1 (es)
EP (1) EP2040691B1 (es)
JP (1) JP2009542589A (es)
KR (1) KR20090031546A (es)
CN (1) CN101484154A (es)
AR (1) AR061812A1 (es)
AT (1) ATE511837T1 (es)
AU (1) AU2007271431A1 (es)
BR (1) BRPI0714012A2 (es)
CA (1) CA2656630A1 (es)
CL (1) CL2007001960A1 (es)
CO (1) CO6160303A2 (es)
CR (1) CR10550A (es)
CY (1) CY1111881T1 (es)
DE (1) DE102006031175A1 (es)
DK (1) DK2040691T3 (es)
EC (1) ECSP089023A (es)
ES (1) ES2366389T3 (es)
GT (1) GT200800310A (es)
IL (1) IL195970A0 (es)
MA (1) MA30600B1 (es)
MX (1) MX2009000012A (es)
PE (1) PE20080554A1 (es)
PL (1) PL2040691T3 (es)
PT (1) PT2040691E (es)
RU (1) RU2009103818A (es)
SI (1) SI2040691T1 (es)
SV (1) SV2009003143A (es)
TN (1) TNSN08517A1 (es)
TW (1) TW200808690A (es)
UA (1) UA94955C2 (es)
UY (1) UY30471A1 (es)
WO (1) WO2008003414A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2115213A1 (en) * 2007-02-08 2009-11-11 Dow Global Technologies Inc. Flexible conductive polymeric sheet
DE102008062689A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Modifikation I der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
DE102008062688A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Monohydrat der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
HUE053745T2 (hu) 2011-11-25 2021-07-28 Adverio Pharma Gmbh Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában
PL2875003T3 (pl) * 2012-07-20 2017-05-31 Bayer Pharma Aktiengesellschaft Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination

Also Published As

Publication number Publication date
IL195970A0 (en) 2009-09-01
PT2040691E (pt) 2011-08-23
ES2366389T3 (es) 2011-10-19
CA2656630A1 (en) 2008-01-10
PE20080554A1 (es) 2008-07-13
US20100069493A1 (en) 2010-03-18
AU2007271431A1 (en) 2008-01-10
RU2009103818A (ru) 2010-08-20
CN101484154A (zh) 2009-07-15
MX2009000012A (es) 2009-01-23
CO6160303A2 (es) 2010-05-20
JP2009542589A (ja) 2009-12-03
CY1111881T1 (el) 2015-11-04
ATE511837T1 (de) 2011-06-15
EP2040691A1 (de) 2009-04-01
SV2009003143A (es) 2009-07-28
PL2040691T3 (pl) 2012-01-31
SI2040691T1 (sl) 2011-10-28
TW200808690A (en) 2008-02-16
CL2007001960A1 (es) 2008-02-01
UA94955C2 (en) 2011-06-25
AR061812A1 (es) 2008-09-24
UY30471A1 (es) 2008-02-29
DK2040691T3 (da) 2011-09-26
MA30600B1 (fr) 2009-07-01
KR20090031546A (ko) 2009-03-26
WO2008003414A1 (de) 2008-01-10
TNSN08517A1 (en) 2010-04-14
CR10550A (es) 2009-06-04
GT200800310A (es) 2009-07-31
BRPI0714012A2 (pt) 2013-04-02
EP2040691B1 (de) 2011-06-08
DE102006031175A1 (de) 2008-01-10

Similar Documents

Publication Publication Date Title
FR25C1030I1 (fr) Sels de lysine de derives d'acide 4-((phenoxyalkyl) thio)-phenoxyacetique
NI200700107A (es) (bifenil) ácidos carboxílicos y sus derivados
CR8218A (es) Antidoto sobre la base de derivados de acidos carboxilicos aromaticos alifaticos
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
ATE514672T1 (de) Säureadditionssalze von 5-aminolevulinsäure oder derivaten davon
ECSP034849A (es) Sales tartrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma
AR060568A1 (es) Acidos bifenilcarboxilicos substituidos y sus derivados
BR0112538A (pt) Sais estáveis de ácido o-acetilsalicìlico com aminoácidos básicos
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
MA29416B1 (fr) Inhibiteurs d'age
MX2007012443A (es) Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.
BRPI0418133A2 (pt) pró-fármaco de florfenicol tendo solubilidade em água melhorada
DOP2010000391A (es) Composicion y proceso-356
SV2009003143A (es) Formulacion farmacologica acuosa de acido 4- [((4-carboxibutil)- {2-[(4-fenetil-bencil)oxi] -fenetil} amino)mentil]benzoico
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
PE20061389A1 (es) Formulacion farmaceutica que contiene biguanida y un derivado de tiazolidinadiona
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"
ATE519737T1 (de) Organische verbindungen
CU20080249A7 (es) Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico
DOP2008000090A (es) Formulacion farmacologica acuosa de acido 4-[((4-carboxibutil)-(2-[(4-fenetil-bencil(oxi]-fenetil)amino]benzoico